Effect of estradiol and raloxifene on MUC1 expression and adhesive properties of Ishikawa cells

Oncology Reports

Volumn 14, Issue 2, 2005, Pages 583-589

  Paszkiewicz Gadek, Anna ^a   Porowska, Halina ^a   Pietruczuk, Miroslawa ^a   Haczynski, Jozef ^b   Kisiel, Dariusz G ^a   Wolczynski, Slawomir ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Adhesion; Estradiol; Ishikawa cell line; MUC1 mucin; Raloxifene

Indexed keywords

ALPHA2 INTEGRIN; ANTIESTROGEN; BETA1 INTEGRIN; CA 15-3 ANTIGEN; EPITOPE; ESTRADIOL; MONOCLONAL ANTIBODY; POLYSACCHARIDE; RALOXIFENE;

ARTICLE; CELL ADHESION; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; ENDOMETRIUM TUMOR; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD29; CA-15-3 ANTIGEN; CELL ADHESION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOMETRIAL NEOPLASMS; EPITOPES; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; FLOW CYTOMETRY; HUMANS; INTEGRIN ALPHA2; POLYSACCHARIDES; RALOXIFENE;

EID: 24744466320     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.2.583     Document Type: Article

References (36)

1. Holinka CF, Hata H, Gravanis A, et al: Effects of estradiol on proliferation of endometrial adenocarcinoma cells (Ishikawa line). J Steroid Biochem 25: 781-786, 1986. (Pubitemid 17227957)
2. Grady D, Gebretsadik T, Kerlikowske K, Ernster V and Petitti D: Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 85: 304-313, 1995.
3. The Writing Group for the postmenopausal estrogen/progestin interventions (PEPI) trial: Effects of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA 275: 1880-1881, 1996.
4. Mourits MJ, Ten Hoor KA, van der Zee AG, Willemse PH, de Vries EG and Hollema H: The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium. J Clin Pathol 55: 514-519, 2002. (Pubitemid 34779303)
5. Lonard DM and Smith CL: Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions. Steroids 67: 15-24, 2002. (Pubitemid 33112000)
6. Barsalou A, Gao W, Anghel SI, Carriere J and Mader S: Estrogen response elements can mediate agonist activity of antiestrogens in human endometrial Ishikawa cells. J Biol Chem 273: 17138-17146, 1998. (Pubitemid 28311750)
7. Jordan VC: Molecular mechanism of action of raloxifene and tamoxifen today and tomorrow. J Natl Cancer Inst 90: 967-971, 1998.
8. Liu H, Park WC, Bentrem DJ, et al: Structure-function relationships of the raloxifene-estrogen receptor-α complex for regulating transforming growth factor-α expression in breast cancer cells. J Biol Chem 277: 9189-9198, 2002. (Pubitemid 34952998)
9. Dardes RC, Schafer JG, Pearce ST, Osipo C, Chen B and Jordan VC: Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells. Gynecol Oncol 85: 498-506, 2002. (Pubitemid 34651892)
10. Delmas PD, Bjarnason NH, Mitlak BH, et al: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometri um in postmenopausal women. N Engl J Med 337: 1641-1647, 1997. (Pubitemid 27510100)
11. Cummings SR, Duong T, Kenyon E, Cauley JA, Witehead M and Krueger KA: Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287: 217-220, 2002.
12. Black LJ, Sato M, Rowley ER, et al: Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93: 63-69, 1994. (Pubitemid 24030821)
13. Sato M, Rippy MK and Bryant HU: Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and non-reproductive tissues in ovariectomized rats. FASEB J 110: 905-912, 1996. (Pubitemid 26184169)
14. Erlandsson M, Josson CA, Lindberg MK, Ohlsson C and Carlsten H: Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice. J Endocrinol 175: 310-327, 2002.
15. Ettinger B, Black DM, Mitlak BH, et al: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomised clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282: 637-645, 1999. (Pubitemid 29384151)
16. Koda M, Jarzabek K, Haczynski J, Knapp P, Sulkowski S and Wolczynski S: Differential effects of raloxifene and tamoxifen on the expression of estrogen receptors and antigen Ki-67 in human endometrial adenocarcinoma cell line. Oncol Rep 12: 517-521, 2004.
17. Nishida M, Kasahara K, Kaneko M, Iwasaki H and Hayashi K: Establishment of a new human endometrial adenocarcinoma cell line, Ishikawa cells, containing estrogen and progesterone receptors. Acta Obstet Gynecol Jpn 37: 1103-1111, 1985. (Pubitemid 15047811)
18. Alaoui-Jamali M, van de Veide P and Mader S: Growth-stimulatory and transcriptional activation properties of raloxifene in human endometrial Ishikawa cells. Mol Cell Endocrinol 19: 65-73, 2002. (Pubitemid 34462052)
19. Satoh S, Hinoda Y, Hayashi T, Burdick M, Imai K and Hollingsworth MA: Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding and an anti-adhesion molecule. Int J Cancer 88: 507-518, 2000.
20. Ligtenberg MJ, Kruijshaar L, Buijs F, Van Meijer M, Litvinov SV and Hilkens J: Cell-associated episialin is a complex containing two proteins derived from a common precursor. J Biol Chem 267: 6171-6177, 1992.
21. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A and Hilkens J: Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 129: 255-265, 1995.
22. Wesseling J, van der Valk SW and Hilkens J: A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 7: 565-577, 1996. (Pubitemid 26112564)
23. Porowska H, Paszkiewicz-Gadek A, Anchim T, Wolczynski S and Gindzienski A: Inhibition of the O-glycan elongation limits MUC1 incorporation to cell membrane of human endometrial carcinoma cells. Int J Mol Med 13: 459-464, 2004.
24. Paszkiewicz-Gadek A, Porowska H, Anchim T, Wolczynski S and Gindzienski A: Biosynthesis of MUC1 mucin in human endometrial adenocarcinoma is modulated by estradiol and tamoxifen. Gynecol Endocrinol 17: 37-44, 2003. (Pubitemid 36349880)
25. Bradford MM: A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
26. Dufour S, Beauvais-Jouneau A, Delouvee A and Thiery JP: Differential function of N-cadherin and cadherin-7 in the control of embryonic cell motility. Cell Biol 146: 501-516, 1999. (Pubitemid 29369784)
27. Marcinkiewicz C, Lobb RR, Marcinkiewicz MM, et al. Isolation and characterization of EMS16, a C-lectin type protein from Echis multisquamatus venom, a potent and selective inhibitor of the alpha2beta1 integrin. Biochemistry 39: 9859-9867, 2000. (Pubitemid 30626834)
28. Barret-Connor E, Grady D, Sashegyi A, et al: Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE randomised trail. JAMA 287: 847-857, 2002. (Pubitemid 34252031)
29. Ismail SM: The effect of tamoxifen on the uterus. Curr Opin Obstet Gynecol 8: 27-31, 1996.
30. Love CD, Muirr BB, Scrimgeour JB, Leonard RC, Dillon P and Dixon JM: Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 17: 2050-2054, 1999. (Pubitemid 29318834)
31. Brayman M, Thathiah A and Carson DD: MUC1: A multifunctional cell surface component of reproductive tissue epithelia. Reprod Biol Endocrinol 2: 1-9, 2004.
32. Ciborowski P and Finn O: Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis J. Clin Exp Metastasis 19: 339-345, 2002. (Pubitemid 34606759)
33. Horne AW, White JO and Lalani E-N: Adhesion molecules and the normal endometrium. Br J Obstet Gynaecol 109: 610-617, 2002. (Pubitemid 37336528)
34. Hynes RO: Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69: 11-25, 1992.
35. Prifti S, Zourab Y, Koumouridis A, Bohlmann M, Strowitzki T and Rabe T: Role of integrins in invasion of endometrial cancer cell lines. Gynecol Oncol 84: 12-20, 2002. (Pubitemid 34056460)
36. Castelbaum AJ, Somkuti SG, Sun J, Ilesanmi AO and Lessey B: Characterization of integrin expression in well-differentiated endometrial adenocarcinoma cell line (Ishikawa). J Clin Endocrinol Metab 82: 136-142, 1997. (Pubitemid 27021284)